Evidence map›Paper›PMID 33579353›Full record

ArticleHereditary cancer in clinical practice2021

Room for improvement: One third of Lynch syndrome patients presenting for genetic testing in a highly specialised centre in Stockholm already have cancer.

Sophie Walton Bernstedt, Jan Björk, Kaisa Fritzell, Allan D Spigelman, Erik Björck, Ann-Sofie Backman

Open access · goldAbstract read
In one paragraph

Article in Hereditary cancer in clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Global medical genetics · 2023
    Article
  3. A common genetic variation inFrontiers in oncology · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sophie Walton BernstedtDepartment of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-4874-4485
Jan BjörkDepartment of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-1903-2171
Kaisa FritzellPatient flow Hereditary Cancer, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-3554-074X
Allan D SpigelmanSt Vincent's Genetics Clinic, The Kinghorn Cancer Centre, Sydney, Australia.ORCID https://orcid.org/0000-0002-7409-1684
Erik BjörckDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Ann-Sofie BackmanDepartment of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. ann-sofie.backman@sll.se.ORCID http://orcid.org/0000-0002-6054-6692
Karolinska University Hospital · SEUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLynch syndrome is caused by germline mutations in the mismatch repair genes and is characterised by a familial accumulation of colorectal and other cancers. Earlier identification of Lynch syndrome patients enables surveillance and might reduce the risk of cancer. It is important to explore whether today's clinical care discovers patients with Lynch syndrome suitable for surveillance in time. This study aimed to describe what led to a diagnosis of Lynch syndrome in the cohort referred to the Hereditary Gastrointestinal Cancer Unit, Karolinska University Hospital, Solna, Sweden for gastrointestinal surveillance.

methodsThis was a descriptive study. Data from 1975 to 2018 were collected and compiled as a database. Age at diagnosis was calculated from the date when a pathogenic MMR gene mutation was confirmed, from the period June 1994-September 2018. Data were collected from patient protocols prospectively during patient consultations and medical records retrospectively. Criteria for inclusion were registration at the outpatient clinic and a confirmed mismatch repair gene mutation.

resultsA total of 305 patients were eligible for inclusion. Three major reasons for diagnosis were identified: 1. Predictive testing of a previously known mutation in the family (62%, mean age 37), 2. A family history of Lynch associated tumours (9%, mean age 37), 3. A diagnosis of cancer (29%, mean age 51). The proportion diagnosed due to cancer has not changed over time.

conclusionA high proportion of patients (29%) were identified with Lynch syndrome after they had been diagnosed with an associated cancer, which suggests that there is significant room for improvement in the diagnosis of patients with Lynch syndrome before cancer develops.

Indexed as

Cancer preventionColorectal cancerGenetic testingLynch syndromeMismatch repair genes

Identifiers

PMID33579353
PMCPMC7881447
OpenAlexW3126695532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.